• Supreme Court Retains Doctrine of Assignor Estoppel, But With Limits

    By Kevin E. Noonan and Joshua R. Rich

    Supreme Court Building #2Patent law is replete with arcane (and often judge-made) doctrines, such as the doctrine of equivalence and obviousness-type double patenting.  In addition, long having been considered a property right (Oil States to the recent contrary), patents have been bound to greater or lesser degrees with equitable considerations attendant on the transfer of property and proper limits thereof.  These two strands of patent law and jurisprudence converge in the doctrine of assignor estoppel, the question before the Court in Minerva Surgical, Inc. v. Hologic, Inc.  On Monday, a five-justice majority of the Supreme Court, reaffirmed the doctrine, while at the same time limiting its application.

    Simply put, assignor estoppel prohibits an inventor or other owner of rights in a patent from selling that patent to another party, then practicing the invention while attempting to avoid infringement liability by claiming the patent was invalid from the start.  The Minerva majority found that the doctrine was well-established in the law and thus was unwilling to abandon it.  However, consistent with the equitable nature of the doctrine, the Court limited the doctrine to those instances where the assignor could be fairly understood to have warranted (either expressly or implicitly) the validity of the claims ultimately issued.  Thus, in many circumstances — such as when an inventor assigns rights to a patent application that ultimately issues with significantly broader claims — the doctrine will not apply.

    In Minerva, the Court faced a clear example of one of the potential exceptions to the rule of assignor estoppel.  The inventor, Csaba Truckai, conceived a device with a moisture-permeable head that could treat abnormal uterine bleeding.  He filed a patent application that described that invention and assigned it to a company he formed.  After he sold the company (including the patent rights), he founded a second company, Minerva Surgical.  At Minerva, he developed a device with a moisture-impermeable head that could also treat abnormal uterine bleeding (the Court's opinion noting that Minerva's device worked in a different manner that the original device disclosed in the putatively infringed patent).  The successor-in-interest to Truckai's first company (Hologic), unhappy with his direct competition, filed a continuation of the original application and pursued claims that would encompass devices regardless of the permeability of the head despite the differences in the two inventions.  Those claims issued and the successor sued Minerva on that patent.  Minerva argued that those later-added claims lacked support in the written description of the application, but the trial court refused even to consider the argument based on the doctrine of assignor estoppel.  Denied the ability to assert invalidity as a defense, Minerva was found to infringe the broader claims.  On appeal, the Federal Circuit agreed with this application of the assignor estoppel doctrine.

    The Supreme Court majority, citing and discussing some of the precedent that established the doctrine of assignor estoppel, found that the doctrine was well established (both before and after the 1952 Patent Act) and that its application should be addressed as a matter of fairness.  If a party sells patent rights based on a representation that the claims are valid, it would be unfair to allow that assignor to come into court and argue that the claims are invalid.  And even if that representation is not explicit in the contract, the assertion of validity of the assigned patent may be implied because the inventors have represented to the Patent and Trademark Office in an oath and declaration that the application disclosed and claimed their invention.  Thus, the patent assignor — who would often be best positioned to compete with the assignee because of experience in the field — should in fairness not be able to raise invalidity as a defense to a patent infringement claim.  But it would similarly be unfair to assignors that had not made such a representation of validity of the claims asserted against them to be precluded from challenging validity.  An example that resonated with the majority was the case of an employee who prospectively assigns all inventions made in the workplace as part of an employment agreement; the employee could scarcely be held accountable regarding claims for a later-developed invention since the invention had not yet been conceived, let alone claimed.  It would also be the case when a patent application is assigned and the claims are later broadened to cover a scope not initially within the claims at the time of the assignment.

    The majority decision, written by Justice Kagan and joined by the Chief Justice and Justices Breyer, Sotomayor, and Kavanaugh, parsed as is the Court's wont the judicial history of the doctrine, which is of much less ancient provenance than other doctrines (a fact upon which Justice Barrett in part bases her dissent).  The principal case is Westinghouse Elec. & Mfg. Co. v. Formica Insulation Co., 266 U.S. 342, 349 (1924), where the Court opined that the doctrine of assignor estoppel was "well-settled" law.  But perhaps more important to the majority was the essential fairness as set forth above, the majority making the distinction that the equitable principles underlying the assignor estoppel doctrine were the stuff of "centuries-old fairness principles," tracing the roots of assignor estoppel in English law (Oldham v. Langmead (1789)) that "grew in favor throughout the 1800s as an aspect of fair dealing," as well as estoppel by deed in English real property law.  Its first appearance in U.S. law was in 1880, Faulks v. Kamp, 3 F. 898 (CC SDNY), and by 1893 was "so well established and generally accepted that citation of authority is useless," Griffith v. Shaw, 89 F. 313, 315 (CC SD Iowa 1893).  And Westinghouse, consistent with the rationale espoused in this precedent, "grounded assignor estoppel in a principle of fairness."

    But the Court also apprehended the circumstances, perhaps present here, where essential unfairness is just as important a consideration.  Such considerations have been present in the Court's application of doctrine in Westinghouse, according to the majority opinion, because the assignor should be allowed to argue how to construe the claims based on the prior art and, for example, obtain a construction narrow enough to avoid infringement.  (In a footnote, the Court acknowledges that while today the practice of the court construing claims limits the opportunity for an assignor to take refuge in this stratagem, the majority notes that "[t]he critical point for our purpose is that even while affirming the assignor estoppel doctrine, the Court made clear that it did not always bar assignors from effectively defending against infringement suits.")  The Westinghouse Court had "left for another day" a question that "most interested" them: "whether estoppel should operate differently if the assignment was not of a granted patent but of a patent application."  The distinction is that for an application the patent right is "inchoate" and not "certainly defined."

    The Court noted that the Federal Circuit, in addition to somewhat slavishly relying on the doctrine, also rejected consideration of Minerva's argument that Hologic had broadened the claims in its patent expressly to ensnare Minerva's device.  This was where the Federal Circuit erred, according to the majority, for not recognizing that "[t]he doctrine applies only when an inventor says one thing (explicitly or implicitly) in assigning a patent and the opposite in litigating against the patent's owner."  The majority announced that it rejected Minerva's call to abrogate the doctrine completely but had decided that the scope of the estoppel should be constrained.  The Court rejected Minerva's contention (persuasive to Justice Barrett) that the 1952 Patent Act abrogated the doctrine by including a provision that invalidity must be available as a defense in every case in 35 U.S.C. § 282(b) because like language was in the Patent Act when Westinghouse was decided.  In addition, such a statutory construction "would foreclose applying in patent cases a whole host of common-law preclusion doctrines" such as equitable estoppel, collateral estoppel, res judicata, and law of the case contrary, inter alia, to cases like SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC, 137 S. Ct. 954 (2017).  Moreover this interpretation would be contrary to the principle that Congress "legislate[s] against a background of common-law adjudicatory principles," a proposition for which the majority cited Astoria Fed. Sav. & Loan Assn. v. Solimino, 501 U.S. 104, 108 (1991).  Thus, the majority opined that assignor estoppel was "such a background principle of patent adjudication" by 1952 that without an express, evident statutory purpose in the Patent Act, the Court was not persuaded by Minerva's argument.

    Nor did the majority believe that its decisions including Lear, Inc. v. Adkins, 395 U.S. 653 (1969), which eliminated licensee estoppel, and Justice Frankfurter's dissent in Scott Paper Co. v. Marcalus Mfg. Co., 326 U.S. 249, 264 (1945), limiting assignor estoppel, had "eviscerated any basis for assignor estoppel."  Rather, the opinion surmised that these decisions did nothing more than "police the doctrine's boundaries" (which is how the Court characterized its decision in this case).  In an amusing aside, the majority characterized the dissent as "worked-up" in its disagreements over the Court's decision in Scott Paper where in the majority's opinion the Court likewise refused to abrogate the assignor estoppel doctrine.  And Lear "gives Minerva still less to work with" the majority thought, being directed to licensee estoppel and reciting dicta that in the assignment context the "equities" are "far more compelling than those presented in the typical licensing arrangement."

    Finally, the Court ignored the clarion call that all of the patent law might be struck down to rid the innovation ecosystem of "bad" patents (and that this provided a sufficient incentive to abrogate the doctrine here).

    While hewing to the equitable application of assignor estoppel in certain instances, the majority believed that the doctrine requires limits.  The most significant of these limits is that it should be applied "only when its underlying principle of fair dealing comes into play."  And where "the assignor has made neither explicit nor implicit representations in conflict with an invalidity defense, then there is no unfairness in its assertion" and assignor estoppel should not apply.  The Court notes the common occurrence that an inventor assigns to an employer "future rights" in patents for later-developed inventions.  Here, it is the assignee that determines which inventions to patent, and thus the assignor can have no representations to make.  But most relevant to this case, the Court notes that the basis for a representation of validity can be diminished — if not abolished — by a change in patent claims, which can arise when an application not yet a granted patent is assigned (as characterized in Westinghouse, comprising an "inchoate" right").  The majority believed that this understanding of the limits of the proper application of the doctrine was the Court's concern in Westinghouse as it is here (appreciating that opinion to have "liberally dropped hints" to that effect).  Thus, the Court set out the rule that:

    Assuming that the new claims are materially broader than the old claims, the assignor did not warrant to the new claims' validity.  And if he made no such representation, then he can challenge the new claims in litigation: Because there is no inconsistency in his positions, there is no estoppel.  The limits of the assignor's estoppel go only so far as, and not beyond, what he represented in assigning the patent application.

    Here, because prior Federal Circuit precedent called for the blanket application of assignor estoppel, there was no record of whether application of the doctrine would be fair; the Federal Circuit's error was in not recognizing the boundaries that the majority enunciate here.  The Court therefore remanded the matter for further consideration on this point.

    Two groups of Justices dissented from the decision; Justice Barrett wrote for three Justices (herself and Justices Thomas and Gorsuch), while Justice Alito wrote for himself alone.

    Unlike the majority, Justice Barrett believed the doctrine was not so well-established that revision of the Patent Act in 1952 could be considered to have adopted (or at least not abrogated) the doctrine.  Justice Barrett's dissent dissected the Court's consideration of the doctrine prior to and after enactment of the 1952 Act and found no basis in the text of the Act for the majority's acceptance that assignor estoppel was so established that Congress could be presumed to have drafted the Act assuming the existence of assignor estoppel as an essential backdrop.  Thus, after coming to the conclusion that the doctrine was not well-established prior to the 1952 Act, Justice Barrett treated the question as one of statutory interpretation.  She found no discussion of assignor estoppel in the plain language of the statute and hence no reason to hold that it had survived the sweeping revisions of patent law enacted by the 1952 Act.

    Justice Alito wrote a separate dissent voicing his opinion that the Court should have considered explicitly whether the clearest precedent regarding the doctrine, Westinghouse v. Formica, should be expressly overruled (which would abrogate the doctrine).  Because neither the majority nor the primary dissent addressed that issue, he believed that the case should not have been considered by the Court at all.

    Minerva Surgical, Inc. v. Hologic, Inc. (2021)
    Opinion by Justice Kagan, joined by Chief Justice Roberts and Justices Breyer, Sotomayor, and Kavanaugh; dissenting opinion by Justice Alito; dissenting opinion by Justice Barrett, joined by  Justices Thomas and Gorsuch

  • By Kevin E. Noonan

    On May 20th, Junior Party the University of California, Berkeley; the University of Vienna; and Emmanuelle Charpentier (collectively, "CVC") filed its Substantive Preliminary Motion No. 1 in Interference No. 106,127 (which names ToolGen as Senior Party), asking the Patent Trial and Appeal Board for benefit of priority to U.S. provisional application No. 61/652,086, filed May 25, 2012 ("P1"), U.S. Provisional Application No. 61/716,256, filed October 19, 2012, ("P2"), and U.S. Provisional Application No. 61/757,640, filed January 28, 2013 ("Provisional 3"), pursuant to 37 C.F.R. §§ 41.121(a)(1)(ii) and 41.208(a)(3) and Standing Order ¶ 208.4.1.  The relationships between the patents and applications in the '127 interference are set forth in this chart (filed in CVC's earlier preliminary motion in the '115 Interference):

    Image 1
    The significance of the Board granting this motion with regard to the P1 or P2 provisional applications would be that CVC would be Senior Party, with all the presumptions benefits of Senior Party status.

    CVC argues that its inventors invented eukaryotic cell CRISPR using a single-molecule guide RNA (sgRNA) that is described in each of the three provisional applications.  Once that breakthrough had been achieved, CVC argues that adapting CRISPR to eukaryotic cell environment would have been "pretty straightforward" (quoting Dr. Luciano Marraffini, who informed the Broad inventors of the sgRNA embodiment in June, 2012 (see "CVC Files Motion in Opposition to Broad Priority Motion").  CVC supports this assertion with contemporaneous consistent statements from Rodolphe Barrangou, Erik Sontheimer, Samuel Sternberg, and Dana Carroll, as well as Jennifer Doudna; by the existence of "existing platforms that had already been successfully used with the two incumbent systems: zinc-finger nucleases ("ZFNs") and transcription activator-like effector nucleases ("TALENs")"; and by the successful practice of CRISPR by several groups (including ToolGen) "[j]ust months after CVC presented this work and the absence in the reports from any of these groups of "any 'special' adaptations or conditions needed to achieve CRISPR gene editing in eukaryotic cells."  Citing extensively from the record in the '115 Interference, CVC asserts that "investigators from Broad copied CVC's system, applied well-known reagents, cell lines, and vectors, and simply followed the manufacturer's protocols to obtain the results that Broad published in 2013 ('Cong 2013')" and that "CVC itself employed expression vectors and techniques commonly used for ZFNs and TALENs to deliver the sgRNA CRISPR-Cas9 system into eukaryotic cells."

    CVC also addresses the PTAB's decision not to grant CVC's patents and applications in the '115 patent the benefit of priority to the P1 and P2 provisional applications sought here; the basis for that decision, according to CVC was that it was made "without the benefit of the now well-developed evidentiary record."  Specifically, CVC argues that "[t]he prior decision credited assertions that have been seriously undermined by evidence presented during the priority phase of the '115 interference."  That record is cured herein, CVC argues, because the motion "presents new evidence and highlights the specific description in P1 (all of which is carried over to P2) not addressed in the PTAB's prior decision on motions," the focus being on the P1 provisional application because an affirmative decision in this priority document would made CVC the Senior Party.  Part of that evidence is that the P1 provisional "contemplates and teaches that the sgRNA CRISPR-Cas9 system can be microinjected as a pre-assembled ribonucleoprotein ("RNP") complex into embryos, including fish cells ("E1"), which obviates the concerns alleged in the '115 interference" (emphasis in brief).  Why these aspects of the P1 disclosure are significant, CVC explains, is that the concerns raised by Broad regarding eukaryotic CRISPR embodiments ("RNA and protein expression, co-localization, and assembly") are avoided because the CRISPR-Cas9 complex is already formed in vitro prior to being microinjected into the embryo.  RNA degradation would also not have been a concern because it was known that sgRNA was protected from degradation in the complex by the Cas9 protein.  Nuclear localization, another putative concern, is avoided by direct microinjection into the nucleus, not would chromatin structure impede CRISPR gene editing activity in embryonic cell because eukaryotic DNA adopts an "open conformation" during cell division in embryos, according to CVC.  Finally, the skilled worker would not expect there to be toxicity of CRISPR complex in eukaryotic cells because, according to the brief, microinjection is known to be a "low toxicity" procedure.

    It should be noted that these arguments take advantage of the principle that reduction to practice requires only one embodiment falling within the scope of the claims and this argument does not address introduction of CRISPR-Cas9 components into non-embryonic eukaryotic cells.  Such embodiments are addressed in the separate argument CVC makes with regard to introduction of CRISPR-Cas9 components into human cells using expression vectors; CVC states that "the alleged concerns have been overstated in [this] context."  For example, CVC notes that P1 discloses use of Cas9 from Streptococcus pyogenes, which causes strep throat and thus "flourishes within the same temperature, pH, and ion concentration ranges as most mammalian cells."  Also disclosed in P1 is the use of nuclear localization signals to facilitate proper location within a eukaryotic cell.

    As to the significance of the Board's earlier decision in the '115 Interference, CVC argues that this decision is non-final (that Interference is on-going and the Board's decisions subject to appeal).  In addition, CVC argues that "[t]he PTAB's decision also gave undue weight to certain statements by Doudna, which were misinterpreted as expressing doubt about whether the system would work in eukaryotes."  Somewhat cleverly (because those statements have proven to be compelling before the Board both in the '115 Interference and the earlier Interference No. 106,048), CVC argues that they are not relevant evidence, because the extent to which CVC's priority applications disclose at least one operative embodiment within the scope of the Count "is an 'objective' assessment of what is disclosed within the 'four corners' of the specification, viewed "from the perspective of a person of ordinary skill in the art," citing Ariad Pharms., Inc. v. Eli Lilly and Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc).  To further provide the Board with evidence contrary to these statements, CVC submits a declaration by Inventor Doudna that places the statements in "proper" context.  And CVC provides authority for the proposition that an inventor's "acknowledgement of the complexities of the science does not negate the disclosure" in Frazer v. Schlegel, 498 F.3d 1283, 1288-89 (Fed. Cir. 2007), in which an inventor admitted a subjective lack of certainty regarding his invention that the Court held did not "negate or contradict" constructive reduction to practice.  Under these circumstances, CVC argues that the Board must "consider the merits anew" in deciding that CVC is entitled to priority benefit to the P1 and P2 provisional applications.

    The brief sets forth the "new evidence" presented in support of their motion:

    • First, the PTAB's decision on motions in the '115 interference did not address whether direct injection of a pre-assembled RNP complex into an embryo, as contemplated by P1, would trigger the same alleged concerns as embodiments relying on vector expression.

    • Second, the PTAB's decision on motions did not address description in P1 regarding: the analogous nature of ZFNs and TALENs; routine uses of nuclear localization signals and codon selection; and the inventors' appreciation of the dynamic nature of chromatin.

    • Third, the PTAB's decision on motions did not consider evidence that has since come to light that undermines the initial allegations by Broad that P1 fails to disclose necessary "special" instructions and adaptations for applying CRISPR-Cas9 in eukaryotic cells.

    • Fourth, Broad's arguments in the '115 interference relied on a misinterpretation of quotes by Doudna and Carroll.  Testimony from Doudna, Carroll, and others with first-hand knowledge (Marraffini, Sontheimer, Barrangou, Sternberg) is provided here, to inform what people in the field thought and the expectation that CRISPR-Cas9 would work in eukaryotes.

    The brief then applies each of these new items of evidence to the disclosure of the P1 and P2 provisional applications in making CVC's argument that both priority documents satisfy the disclosure requirements for CVC to be entitled to priority benefit.  This argument involves a comparison between eukaryotic CRISPR and successful microinjection of ZFNs and TALENS known in the prior art; that the skilled worker would have considered these systems to be the closest analogous systems to CRISPR-mediated gene editing in eukaryotic cells; that ToolGen itself had admitted the similarities between CRISPR-, ZFN-, and TALEN-mediated gene editing in eukaryotic cells; and that the other systems used by the Board as (negative) comparators in the '115 Interference (such as Group II introns, ribozymes, and riboswitches) were not apposite.

    Moreover, CVC asserts once again the evidence that, once sgRNA was disclosed by Doudna et al., several (six) groups used it to achieve successful CRISPR-mediated gene editing in eukaryotes.  The brief sets out relevant details of each of these groups' successes:  for Broad:

    Table 1 Table 2
    for ToolGen:

    Table 3
    for Harvard:

    Table 4
    and for Sigma:

    Table 5
    The brief also sets forth in detail the correspondence between the elements of the Count in the Interference and the disclosure in the P1 (and P2) references for each of these embodiments (E1, E2, and E3):

    Table 6
    wherein CVC asserts (as it did in the '115 Interference; see "Berkeley Files Substantive Motion No. 2 to be Accorded Benefit to Earlier Priority Application in Interference") the three embodiments CVC contends fall within the scope of the Count (designated E1 for introduction into fish embryos; E2 for introduction into human cells; and E3 for introduction into fruit fly cells) and that the P1 (and P2) provisional applications thus disclose constructive reduction to practice of CRISPR-Cas9 gene editing in eukaryotic cells.  CVC also sets forth examples of third parties using similar embodiments of their CRISPR technology published after the filing date (May 25, 2012) of the P1 provisional application:

    Table 7
    The brief also addresses the "concerns alleged in the '115 interference" and attempts to allay them for the Board, enumerating RNA degradation; co-localization of the components of the CRISPR-Cas9 complex; cellular conditions; nuclear localization; codon optimization; the effects of chromatin structure and toxicity, none of which are relevant, as CVC argues, for eukaryotic CRISPR-Cas9 embodiments using microinjection of in vitro assembled CRISPR-Cas9 complexes.

    Similar explication and explanation, particularly of the E2 embodiment introducing CRISPR-Cas9 into human cells using an expression vector are set forth in CVC's brief; in this regard the brief similarly addresses the "concerns" asserted against the P1 and P2 provisional applications in the '115 Interference, while at the same time discounting these concerns as "(i) . . . not [being] recited elements of the count and (ii) . . . not [being] required for practicing an embodiment within the scope of the count."  Much of these arguments rely on what the person of ordinary skill in the art would have understood at the time, such as using strong promoters to produce effective amounts of the sgRNA and Cas9 protein; using NLSs to increase nuclear localization likelihood; using S. pyogenes-derived Cas9 that purportedly "flourish" under eukaryotic cellular conditions; and that the P1 (and P2) disclosure recognize that chromatin structure is sufficiently "dynamic" for the CRISPR-Cas9 complex to gain access to portions of the genome targeted by the sgRNA for CRISPR-mediated gene editing to be achieved.

    CVC argues in the alternative that should the Board find wanting its disclosure evidence in the P1 provisional application, the P2 application contains additional disclosure that satisfies the requirements for constructive reduction to practice of at least one embodiment of the invention falling within the scope of the interference Count.

    In a separate section, prefaced by the assertion that it is "not required," CVC sets forth statements contemporaneous with the P1 and P2 provisional application filing dates that eukaryotic embodiments of CRISPR using sgRNA were expected to be operative in eukaryotic cells.  These statements were made, according to CVC, by Luciano Marraffini; Erik Sontheimer; Rodolphe Barrangou (wherein each of the foregoing were present and heard Jennifer Doudna's disclosure of sgRNA CRISPR embodiments at the Fifth Annual CRISPR Research Conference held at Berkeley in June of 2012); Dana Carroll, editor of a review article on CRISPR; Samuel Sternberg (a graduate student in the Doudna laboratory); and Jennifer Doudna herself (offering the "context" CVC intends to use to rebut Broad's negative interpretations of her statements regarding prospects for eukaryotic CRISPR embodiments).

    Finally, CVC sets out the continuous priority chain from the P1 provisional application through the applications and patents at issue in this interference, as set forth in the diagram above.

  • By Kevin E. Noonan

    In Interference No. 106,115 between Senior Party the Broad Institute (joined by Harvard University and MIT) and Junior Party the University of California, Berkeley; the University of Vienna; and Emmanuelle Charpentier (collectively, "CVC"), the Patent Trial and Appeal Board granted CVC's Preliminary Motion for benefit of priority to U.S. Provisional Application No. 61/757,640, filed January 28, 2013 ("Provisional 3"), pursuant to 37 C.F.R. §§ 41.121(a)(1)(ii) and 41.208(a)(3) and Standing Order ¶ 208.4.1.  In Interference No. 106,127, Senior Party ToolGen filed its Substantive Preliminary Motion No. 1 to deny CVC priority benefit to the '640 provisional application.

    The relationships between the patents and applications in the '127 interference are set forth in this chart (filed in CVC's earlier preliminary motion in the '115 Interference):

    Image 1
    ToolGen (stating that Broad did not substantively challenge CVC's assertion of this priority) challenges CVC's entitlement to priority benefit to the P3 provisional here on the grounds that it did not disclose "successful cleavage of DNA within eukaryotic cells, nor does it otherwise show a constructive reduction to practice of an embodiment within Count 1."

    ToolGen's argument depends on three assertions.  First, the brief identifies a single Example (Example 2) in the P3 provisional application directed towards purported eukaryotic cell embodiments of CRISPR gene editing (which, if it provided an adequate description of even a single enabled embodiment would be sufficient to satisfy the requirement for priority).  Second, ToolGen asserts that the Example (and Figures 38B and 36E related thereto) do not provide such an adequate description because "Figure 38B shows alleged cleavage bands at positions where there should be none and in some instances no bands where there should be bands."  Similarly, ToolGen asserts that Figure 36E "independently contains so many unexplained bands as to make it so shaky and unreliable that a [person of ordinary skill in the art or] POSA would not view it as showing possession of an embodiment within Count 1."  Taken together, ToolGen argues that "the Figures cannot be evidence that discloses successful cleavage to a POSA in eukaryotes, and the applicants' failure to sequence the resulting products further cements this conclusion."  Third, ToolGen argues that "applicants lysed the cells before DNA extraction such that they left the Cas9 protein active to cleave DNA outside of intact cells, as opposed to within the eukaryotic cell as required by Count 1" and "a POSA would understand that any cleavage shown in the gel results cannot confirm that cleavage occurred within eukaryotic cells."  Like U.S. provisional applications 61/652,086 ("P1") and 61/716,56 ("P2") (for which the Board refused to recognize priority for failure to disclose an adequate description of even a single enabled embodiment of CRISPR in a eukaryotic cell), ToolGen argues that the P3 provisional application is similarly deficient and the Board should deny CVC the accorded priority benefit.

    After setting forth the statutory requirements for a party to be accorded benefit of priority and discussing the level of ordinary skill in the art, ToolGen sets forth its analysis of the deficiencies in the P3 disclosure synopsized above. Supported by expert testimony (Dr. Turchi), ToolGen argues that a POSA at the time of the invention would not have considered the P3 disclosure to satisfy these requirements. Like Broad, ToolGen argues that "adapting the native prokaryotic CRISPR-Cas9 system to cleave DNA within eukaryotic cells was highly unpredictable." Like Broad before it ToolGen enumerates the many differences between the prokaryotic milieu where CRISPR was expressed natively and eukaryotic cells (the existence of the nucleus, packaging genomic DNA in chromatin, the intracellular components for gene expression in eukaryotic cells, and the resulting uncertainty ToolGen alleges arises as a consequence regarding whether the CRISPR-Cas9 system could be adapted for use in these cell types. (An uncertainty ToolGen notes that the Board acknowledged supported by the now infamous, improvident statements by CVC's inventors.)

    Besides these somewhat theoretical obstacles (which, had CRISPR been readily reduced to practice would not have their current asserted significance), ToolGen critically reviews what it contends are deficiencies in the disclosure of Example 2 as illustrated by Figures 38B and 36E (as these deficiencies were attested to by ToolGen's expert witness).  This analysis was set out graphically to show the expected DNA fragments and sequences that the skilled worker would expect and need to observe to conclude successful CRISPR gene editing in the HEK293T human embryonic kidney cells used in the experiments disclosed in Example 2 of the P3 provisional application:
    Image 2
    The brief then sets out the bands produced by successful CRISPR according to ToolGen's expert:

    • A 369 bp PCR product band because not all of the DNA would have been cleaved.  Any larger bands would be unexpected because the PCR product should contain only 369 bp DNA fragments in all lanes.
    • Approximately 183 and 186 bp Cas9-sgRNA cleavage bands in the lanes with both Cas9 and sgRNA.
    • Approximately 162-169 and 200-207 bp ZFN cleavage bands in the ZFN positive control lane.

    Instead of these results, the brief (relying of ToolGen's expert) asserts that:

    If the Figure 38B and 36E gels showed successful DNA cleavage at the target site, a POSA would expect the data in the gels to be consistent with the above.  They are not.  Rather, Figure 38B contains bands that differ significantly from the bands that a POSA would expect if cleavage had been successful.  Figure 36E shows results inconsistent with Figure 38B, and also contains so many unexplained bands as to render the data unreliable—and a POSA would view it as insufficient to demonstrate possession [citations to exhibits omitted].

    The brief further sets forth an "annotated" version of Figure 38B to illustrate its purported deficiencies:

    Image 3
    ToolGen's expert's analysis is set forth in the brief as follows (citations to the exhibits omitted):

    The ~378 bp PCR band (band 1) is consistent with the predicted 369 bp full-length PCR band.  In contrast, the digestion product (band 2)—which the applicants claim is a CRISPR-Cas9 cleavage band—is not the expected size in any of the Cas9-sgRNA lanes (Lanes F, H, and I).  As Dr. Turchi explains, the supposed cleavage band in Figure 38B measures ~280 bp (band 2)—almost 100 bp longer than the expected ~185 bp.  There is no band at all in the expected ~185 bp range—which should have been identifiable at slightly below the 200 bp control ladder marker.  It is also irreconcilable with the sizes of the other bands.

    If the ~280 bp band (band 2) was a digestion band from the ~378 bp PCR band (band 1), there is an unaccounted for ~98 bp DNA fragment, making it unlikely that the ~280 bp band is an actual cleavage band.  Ex. 1410   88; F23.  There are also several unexpected bands—larger than the PCR band—of unknown origin that disappear upon digestion (bands 5 and 6).  Therefore, it is possible that the alleged cleavage band (band 2) comes from one of the larger, digestion sensitive bands and not the PCR band.

    Accordingly, because "applicants nowhere address the irregularities in Figure 38B or provide a POSA with any comfort that they possessed an embodiment within Count 1" and thus "a POSA at the time P3 was filed would find Figure 38B to be unreliable and would have disregarded it in its entirety."

    The brief then sets forth a similar analysis of the experimental results shown in Figure 36E.  The bands found in this Figure should be the same as those in Figure 38B, according to ToolGen's expert, but it does not.  One deficiency is the presence of additional bands; as stated in the brief, "[a]lmost every lane has more than one unexpected band, making it impossible to determine the origin of each digestion product band, which P3 does not attempt to explain."  As with Figure 38B, ToolGen's expert prepared an annotated version of this Figure:

    Image 4
    As explained by ToolGen's expert:

    The PCR band (band 1) measures ~352 bp, consistent with its expected size.  The applicants rely on a single ~173 bp band (band 5) in Lane E to indicate CRISPR10 Cas9 cleavage at the target site.  However, the alleged cleavage band (band 5) could just as easily be a digestion product of the unexpected ~477 bp band (band 2) in Lanes B, D, and F that disappear upon digestion in the Surveyor assay Lanes E and G.  This is fully consistent with the presence of an unexpected digestion band at ~297/312 bp (band 3) also in Lanes E and G, because the unexpected ~477 bp band (band 2) could have been digested into the ~173 and ~297/312 bp digestion product bands (bands 5 and 3, 4 respectively).  And there is yet another unexpected digestion product band at ~252 bp (band 4) in Lanes E and G, which could reflect the unexpected ~477 bp band (band 2) being digested into two equal DNA fragments.  These anomalies would leave the POSA unconvinced of the applicants' possession of an embodiment within Count 1.

    As Dr. Turchi notes, a digestion band is visible in Lane G—between the two ZFN cleavage bands—of similar size and intensity as the purported cleavage band (band 5) in Lane E.  This digestion band is significant because it would further lead a POSA to conclude that band 5 in Lane E is simply a digestion product of one of the larger unexpected band (band 2) in the undigested lanes (Lanes, B, D, and F), and not indicative of successful Cas9 cleavage at the target site.

    From this analysis ToolGen's expert opines that the evidence in Figure 36E is "inconclusive" and "riddled with anomalies and uncertainties" sufficiently inconsistent with CVC's assertion of successful practice of CRISPR-Cas9 in eukaryotic cells that these assertions would not be believed by a person of ordinary skill in the art.

    In view of the asserted poor quality of these experimental results, ToolGen further asserts that the skilled worker "next have performed sequencing on the PCR product to confirm and characterize any potential cleavage results."  Yet, as the brief notes, "no such work was reported in [the] P3 [provisional application]."

    As the final asserted defect in the evidentiary support for CVC's purported reduction to practice of CRISPR in eukaryotic cells, the brief then sets forth its argument that the way the cells were lysed after introduction of CRISPR-Cas9 could have permitted any observed cleavage to have occurred after lysis and thus fall outside the scope of the invention as defined by the Count.  This is illustrated in annotated Figure 37A:

    Image 5
    As set forth in the brief, "the presence of two bands indicates to a POSA that the plasmid was successfully cleaved extracellularly at the predicted Cas9-sgRNA target site and the donor plasmid restriction enzyme site" (emphasis added).  As a consequence, the brief goes on to say that "[t]he results shown in Figure 37A undermine any arguable cleavage results in Figures 38B and 36E because they show that extracellular cleavage occurred in cell lysates prepared using the same Cas9-preserving protocol that was used to prepare the cell lysate in Figure 38B and 36E [emphasis in the brief].  Because the applicants preserved the activity of Cas9 in the lysate, any alleged cleavage shown in Figures 38B or 36E could have occurred outside the cells, in the lysate."

    In addition, the relative cleavage efficiencies between the ZFN positive control and the purported CRISPR-Cas9 lanes further support the conclusion that such CRISPR-Cas9-mediated cleavage occurred in vitro in the lysis buffer and thus does not support reduction to practice of eukaryotic cell embodiments of CRISPR gene editing by CVC in the P3 provisional priority document.

    ToolGen thus asks the Board to rule that CVC is not entitled to the benefit of priority of the P3 provisional application.

  • CalendarJune 29, 2021 – "Proud Innovation — Learn from LGBTQ+ Innovators" (U.S. Patent and Trademark Office) – 1:00 to 3:30 pm (ET)

    June 30, 2021 – "Patentability of Simulations at the EPO" (J A Kemp) – 16:00 pm BST (GMT+1)

    June 30, 2021 – "Waiving IP Protections to Address COVID-19: The WTO Proposals and Ensuring Equitable Access to the Vaccines" (Intellectual Property Owners Association) – 12:00 pm to 1:00 pm (ET)

    June 30, 2021 – "The Better Part of Valor? Discretionary Institution in PTAB Proceedings" (Fitch Even) – 12:00 pm to 1:00 pm (ET)

    July 21-22, 2021 – Advanced Summit on Life Sciences Patents conference (American Conference Institute)

    July 27-28, 2021 – Practitioners' Think Tank on ITC Litigation and Enforcement conference (American Conference Institute)

    July 28-29, 2021 – Women Leaders in Life Sciences Law conference (American Conference Institute)

  • June-29-lgbtq-event-1500px
    The U.S. Patent and Trademark Office will host an online event entitled "Proud Innovation — Learn from LGBTQ+ Innovators" on June 29, 2021 from 1:00 to 3:30 pm (ET).  The event will consist of two panels:

    • Inspiring innovation: A discussion on creating change and building a legacy
    • Creating opportunities: A conversation about building networks and securing funding

    Those interested in attending the panel discussion can do so here.

  • J A KempJ A Kemp will be offering a webinar entitled "Patentability of Simulations at the EPO" on June 30, 2021 at 16:00 pm BST (GMT+1).  John Leeming of J A Kemp will detail the approach of the EPO to computer-implemented inventions (including simulations) and consider what the recent G 01/19 does (and does not) tell us about the patentability of simulations and computer-implemented inventions in general, and also provide practical advice regarding the drafting and prosecution of applications directed to computer-implemented inventions in Europe in light of the decision.  The webinar will address the following topics:

    • The EPO's general approach to computer-implemented inventions
    • What G 01/19 tells us about how this approach should be applied to simulation inventions
    • Further guidance in the decision regarding how the EPO views important concepts such as technicality
    • Practical tips for drafting applications directed to computer-implemented inventions in light of G 01/19
    • Helpful arguments that can be deployed in prosecution

    There is no registration fee for this webinar.  However, those interested in registering for the webinar, should do so here.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Waiving IP Protections to Address COVID-19: The WTO Proposals and Ensuring Equitable Access to the Vaccines" on June 30, 2021 from 12:00 pm to 1:00 pm (ET).  Tanuja Garde of Raytheon Technologies; David Kappos of Cravath, Swaine & Moore LLP; James Pooley of James Pooley, PLC; and Tony Rollins of Rollins IP Strategies Ltd. will share information about the status of the waiver proposals made by India and South Africa and the European Union's proposal to increase the global supply of COVID-19 vaccines, the logistics of negotiations at the WTO, and the roles of various U.S. governmental and international agencies.  The panel will also discuss questions such as whether a waiver would actually increase access to vaccines and other technologies, the impact of a waiver on innovation, impediments to ensuring broader vaccine access, and the effectiveness of ongoing voluntary efforts to distribute the vaccine and other important technologies more widely.

    The registration fee for the webinar is $150 for non-members or free for IPO members (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Fitch EvenFitch Even will be offering a webinar entitled "The Better Part of Valor? Discretionary Institution in PTAB Proceedings" on June 30, 2021 from 12:00 pm to 1:00 pm (ET).  David A. Gosse and Karen J. Wang of Fitch Even will discuss the following topics:

    • How the PTAB exercises its discretion to deny institution in the face of parallel district court proceedings, e.g., in the Western District of Texas "rocket docket"
    • Whether prior reexamination, IPR, PGR, or even prosecution will cause the PTAB to exercise its discretion and deny institution
    • Why the PTAB may or may not deny institution of multiple petitions challenging a single patent

    While there is no cost to participate in the program, advance registration is required.  Those interested in attending the webinar can register here.

  • ACIAmerican Conference Institute (ACI) will be holding its 19th Advanced Summit on Life Sciences Patents conference on July 21-22, 2021 as a virtual conference.

    The conference will offer presentations on the following topics:

    • Refining global patenting strategies in the U.S., Europe, China, and Brazil
    • Gauging the continued impact of the COVID-19 pandemic, including compulsory licensing and march-in rights
    • A PTAB year in review, including latest developments at the Board, the Federal Circuit, and an update on the Arthrex case
    • Future landscape of Section 101: Will there ever be clarity?
    • An international perspective on written description and enablement standards in antibody claims
    • Examining the recent surge in doctrine of equivalents decisions
    • Developments in patent term extensions in the U.S. and Europe, including the implications of Biogen v. Banner and Europe's SVC manufacturing waiver
    • Obviousness, obviousness-type double patenting, and inherency
    • Method of treatment and second medical use claims, personalized medicine and dosage regime patents
    • Separate interactive sessions from life sciences litigators regarding what they wish the prosecutor had done, the implications on skinny labels of GSK v. Teva, and ethical dilemmas in patent prosecution

    The registration fee for the conference is $1,595 if registered and paid by July 2nd and $1,695 if registered and paid by July 20th.  There is an in-house counsel rate of $1,295 available until July 20th.  Patent Docs readers are entitled to a 10% discount off of registration using discount code D10-762-762DX03.  Those interested in registering for the conference can do so here, by e-mailing CustomerService@AmericanConference.com, or by calling 1-888-224-2480.

    Patent Docs is a media partner of ACI's 19th Advanced Summit on Life Sciences Patents Conference.

  • ACIAmerican Conference Institute (ACI) will be holding its 13th Annual Practitioners' Think Tank on ITC Litigation and Enforcement conference on July 27-28, 2021 as a virtual conference.

    The conference will offer presentations on the following topics:

    • ITC State of the Union: Predictions for the future
    • ITC Year in Review, including the Top Ten developments in 2021 and forecasts for 2022
    • Evaluation of trade secret jurisprudence at the ITC
    • Public interest considerations in 337 investigations
    • Discretionary denials and developments in parallel proceedings before the ITC and PTAB
    • Satisfaction of the domestic industry requirement
    • New NPE 337 tactics and what ITC practitioners need to know in 2021
    • In-house counsel perspectives, including insights and best practices for managing ITC actions
    • Winning strategies for enforcing exclusion orders
    • ALJ insights on procedures and effective trial strategies
    • How to maneuver the 100-day early disposition program and assessing its merits
    • Keynote addresses from ITC leaders and 1:1 virtual networking

    The registration fee for the conference is $1,295 if registered and paid by June 18th and $1,895 if registered and paid by July 26th.  Patent Docs readers are entitled to a 10% discount off of registration using discount code D10-868-868DX02.  Those interested in registering for the conference can do so here, by e-mailing CustomerService@AmericanConference.com, or by calling 1-888-224-2480.

    ACI is offering a limited amount of complimentary in-house passes to their 13th Annual Practitioners' Think Tank on ITC Litigation and Enforcement conference.  Apply for your complimentary pass here.

    Patent Docs is a media partner of ACI's 13th Annual Practitioners' Think Tank on ITC Litigation and Enforcement Conference.